104 / 1631
Nivolumab in Patients With Relapsed or Refractory Hematologic
Malignancy: Preliminary Results of a Phase Ib Study.
Lesokhin A et al J Clin Oncol. 2016 Aug 10;34(23):2698-704.
•
Phase 1 study, 81 patients with B-cell malignancies
•
(NHL
n
= 31, including DLBCL [
n
= 11], and FL [
n
= 10]) other B cell
NHL, T cell lymphoma (
n
= 23), and multiple myeloma (
n
= 27); treated
with Nivolumab 3 mg/kg (NCT01592370).
•
All patients had received prior systemic treatment regimens (median 3;
range, 1–12).